February 2011

CONTENTS

SHORT COMMUNICATIONS


Altered Cytochrome P450 Expression in Mice during Pregnancy. Kwi Hye Koh, Hui Xie, Ai-Ming Yu, and Hyunyoung Jeong

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions. Eleanor J. Guest, Leon Aarons, J. Brian Houston, Amin Rostami-Hodjegan, and Aleksandra Galetin

ARTICLES

Morphine Brain Pharmacokinetics at Very Low Concentrations Studied with Accelerator Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry. Muhammad Waqas Sadiq, Mehran Salehpour, Niklas Forsgard, Göran Possnert, and Margareta Hammarnlund-Ulendaeus

Human CYP2S1 Metabolizes Cyclooxygenase- and Lipooxygenase-Derived Eicosanoids. Peter Bui, Satoshi Inaizumi, Sudheer Reddy Beedanagari, Srinivasa T. Reddy, and Oliver Hankinson

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerlin, and Christopher J. Patten

Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways. Markus Zollinger, Hans-Peter Gschwind, Yi Jin, Claudia Sayer, Frédéric Zécri, and Stefan Hartmann

Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thienopyridine Antiplatelet Agent, Prasugrel. Katsunobu Hashihara, Miho Kazui, Atsushi Kurihara, Kazuhi Kubota, and Toshihiko Ikeda

Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. Cecilia Renculli, Mike Nash, Mark Wright, Steven Thomas, Stefano Zanuner, Marco Pellegrato, Paolo Bettica, and Gary Boyle

Metabolism and Disposition of 13C-Labeled Peliglitzar in Humans. Lifei Wang, Carey Mumick, Sean Chen, Samuel Bonacorsi, Peter T. Cheng, W. Griffith Humphreys, and Donglu Zhang


Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Martin N. Fransson, Henrik Green, Jan-Eric Littge, and Lena E. Friberg

Tissue Distribution and Elimination of [14C]Apixaban in Rats. Lifei Wang, Kan He, Brad Maxwell, Scott
Contents (cont’d.)

J. Grossman, Larry M. Tremaine, W. Griffith Humphreys, and Donglu Zhang ............... 256

Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model. Xuena Lin, Suzanne Skolnik, Xiao-hui Chen, and Jianling Wang ....... 265

The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. Robert Elsby, Michael Gillen, Caroline Butters, Gemma Inimsson, Pradeep Sharma, Veronica Smith, and Dominic D. Surry ............ 275

Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant. Sabrina Pa-gliaruso, Silvia Martinucci, Ellenia Bordini, Lidia Miraglia, Domenico Cufari, Luca Ferrari, and Mario Pellegratti ............... 283

A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat. R. Lledo ´-García, A. Na ´cher, V. G. Casabo ´, and M. Merino-Sanjua´n .............. 294


Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federica Vinco, Simome Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss ............... 312

Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Jin Zhou, Timothy S. Tracy, and Rory P. Remmel ............... 322

Ethanol Induction of CYP2A5: Permissive Role for CYP2E1. Yongke Lu, Jian Zhuge, Defeng Wu, and Arthur I. Cederbaum ............... 330

Identification and Validation of Novel Human Pregnan e X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan ...... 337

Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson ............... 345

ERRATUM
Correction to “Identification of Clinically Utilized Drugs that Activate Pregnan e X Receptors” ... 351

S Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Molecular modeling showing the binding of OSI-930 in the active sites of P450 3A4 (A) and P450 3A5 (B). See the article by Lin et al. on page 345 of this issue.